| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0083-6729(09)81009-1 |
| P698 | PubMed publication ID | 19647114 |
| P50 | author | Leyre Mestre | Q59680276 |
| Fabian Docagne | Q48490748 | ||
| P2093 | author name string | Carmen Guaza | |
| Fernando G Correa | |||
| José Borrell | |||
| P2860 | cites work | Glutamate excitotoxicity in a model of multiple sclerosis | Q60450917 |
| Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation | Q60597674 | ||
| Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells | Q61479730 | ||
| Therapeutic potential of CB2 targeting in multiple sclerosis | Q80521829 | ||
| The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis | Q48108020 | ||
| Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase | Q48251232 | ||
| Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. | Q48257647 | ||
| Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. | Q48448864 | ||
| Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish | Q55871276 | ||
| Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations | Q24309438 | ||
| Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase | Q24555807 | ||
| Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors | Q24642509 | ||
| A biosynthetic pathway for anandamide | Q24671032 | ||
| Endocannabinoids control spasticity in a multiple sclerosis model | Q28142626 | ||
| Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains | Q28189423 | ||
| Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid | Q28202306 | ||
| CB1 cannabinoid receptors and on-demand defense against excitotoxicity | Q28207143 | ||
| Presence and regulation of the endocannabinoid system in human dendritic cells | Q28216698 | ||
| Structure of a cannabinoid receptor and functional expression of the cloned cDNA | Q28240076 | ||
| Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism | Q28252850 | ||
| Role of CB2 receptors in neuroprotective effects of cannabinoids | Q28269610 | ||
| Identification and functional characterization of brainstem cannabinoid CB2 receptors | Q28276972 | ||
| 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain | Q28290395 | ||
| Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors | Q28292914 | ||
| The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases | Q28293496 | ||
| Molecular characterization of a peripheral receptor for cannabinoids | Q28298338 | ||
| Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide | Q28370516 | ||
| Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice | Q28469322 | ||
| Microglia: active sensor and versatile effector cells in the normal and pathologic brain | Q29547240 | ||
| Isolation and structure of a brain constituent that binds to the cannabinoid receptor | Q29547476 | ||
| Interleukin-12 and the regulation of innate resistance and adaptive immunity | Q29614602 | ||
| International Union of Pharmacology. XXVII. Classification of cannabinoid receptors | Q29616832 | ||
| Formation and inactivation of endogenous cannabinoid anandamide in central neurons | Q29620558 | ||
| Cannabinoid receptor signaling. | Q30353713 | ||
| Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain | Q31570267 | ||
| Like cops on the beat: the active role of resting microglia | Q33223413 | ||
| COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord | Q33235278 | ||
| Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. | Q33845285 | ||
| Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor | Q33964574 | ||
| Nonpsychotropic cannabinoid receptors regulate microglial cell migration. | Q34179008 | ||
| Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. | Q34397288 | ||
| The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications | Q34439965 | ||
| Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes | Q34497846 | ||
| Cannabinoid receptors in microglia of the central nervous system: immune functional relevance | Q34561539 | ||
| The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. | Q34589360 | ||
| Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection | Q34597537 | ||
| Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. | Q34707322 | ||
| Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system | Q34745063 | ||
| Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide | Q34801333 | ||
| The endocannabinoid system is modulated in response to spinal cord injury in rats | Q34859495 | ||
| Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212 | Q34912871 | ||
| New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis | Q35098586 | ||
| Endocannabinoids potently protect the newborn brain against AMPA-kainate receptor-mediated excitotoxic damage | Q35546025 | ||
| Cannabinoid signaling in glial cells | Q35897353 | ||
| Cannabinoid-based drugs as anti-inflammatory therapeutics | Q36111923 | ||
| Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors | Q36155353 | ||
| Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction | Q36482564 | ||
| Cannabinoid receptor 2 (CB2) mediates immunoglobulin class switching from IgM to IgE in cultures of murine-purified B lymphocytes | Q36711079 | ||
| P2X7 receptors control 2-arachidonoylglycerol production by microglial cells | Q36854779 | ||
| Therapeutic potential of cannabinoid-based drugs. | Q36916320 | ||
| CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies | Q36949750 | ||
| Endocannabinoid signaling in microglial cells | Q37250243 | ||
| Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression | Q39987047 | ||
| Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells | Q40158906 | ||
| Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. | Q40440754 | ||
| Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism | Q40593008 | ||
| Differential expression and regulation of IL-23 and IL-12 subunits and receptors in adult mouse microglia | Q40624801 | ||
| Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor | Q40638952 | ||
| Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase | Q40658993 | ||
| Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway. | Q40677598 | ||
| Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation | Q40757331 | ||
| Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. | Q41002908 | ||
| Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells | Q41191282 | ||
| Dopamine activation of endogenous cannabinoid signaling in dorsal striatum | Q41646203 | ||
| Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation | Q43503383 | ||
| Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. | Q43641975 | ||
| Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures | Q43916584 | ||
| Astrocytes in culture produce anandamide and other acylethanolamides. | Q43935534 | ||
| Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide | Q44002298 | ||
| A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. | Q44124410 | ||
| Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells | Q44225647 | ||
| Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide | Q44267931 | ||
| Novel selective and metabolically stable inhibitors of anandamide cellular uptake | Q44430771 | ||
| Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes | Q44477397 | ||
| Cannabinoids inhibit neurodegeneration in models of multiple sclerosis | Q44522438 | ||
| Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. | Q44524201 | ||
| Cannabinoid receptors and T helper cells | Q44740861 | ||
| Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity | Q44840035 | ||
| A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes | Q45000502 | ||
| Therapeutic action of cannabinoids in a murine model of multiple sclerosis. | Q45047941 | ||
| Genetic deletion of Fatty Acid Amide Hydrolase results in improved long-term outcome in chronic autoimmune encephalitis | Q45333654 | ||
| The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection | Q45413276 | ||
| The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway | Q45753821 | ||
| Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes | Q45761757 | ||
| Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. | Q46083107 | ||
| A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells | Q46320828 | ||
| Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. | Q46514030 | ||
| Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis | Q46533142 | ||
| Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. | Q46639969 | ||
| Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis | Q46768353 | ||
| The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells | Q46875092 | ||
| Endocannabinoid, anandamide in gingival tissue regulates the periodontal inflammation through NF-kappaB pathway inhibition | Q46889206 | ||
| Anandamide inhibits IL-12p40 production by acting on the promoter repressor element GA-12: possible involvement of the COX-2 metabolite prostamide E(2). | Q46931542 | ||
| P921 | main subject | anandamide | Q410228 |
| cannabinoids | Q422936 | ||
| endocannabinoids | Q10483908 | ||
| multiple sclerosis | Q8277 | ||
| P304 | page(s) | 207-230 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | Vitamins and Hormones | Q15753296 |
| P1476 | title | The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis | |
| P478 | volume | 81 |
| Q26865295 | Brain innate immunity in the regulation of neuroinflammation: therapeutic strategies by modulating CD200-CD200R interaction involve the cannabinoid system |
| Q34219132 | Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters |
| Q39000393 | Inhibition of COX-2-mediated eicosanoid production plays a major role in the anti-inflammatory effects of the endocannabinoid N-docosahexaenoylethanolamine (DHEA) in macrophages |
| Q89579808 | Neuroprotection Following Concussion: The Potential Role for Cannabidiol |
| Q30506148 | Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice. |
| Q42272971 | β-Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR-α, PPAR-γ and TRPV1, but not CB₁ or CB₂ receptors |
Search more.